北京热景生物技术股份有限公司2025年年度业绩预告

Group 1 - The company forecasts a revenue of between 400 million to 420 million yuan for the year 2025, representing a year-on-year decrease of 17.79% to 21.71% compared to 2024 [1] - The projected net profit attributable to the parent company is expected to be between -210 million to -230 million yuan, indicating an increase in losses of 9.94% to 20.42% compared to the previous year [1] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, is anticipated to be between -250 million to -270 million yuan [1] Group 2 - In 2024, the company reported a revenue of 510.9 million yuan [2] - The net profit attributable to the parent company for 2024 was -191.0046 million yuan [2] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, was -231.1898 million yuan [3] Group 3 - The decline in net profit and net profit after deducting non-recurring gains and losses is primarily due to the impact of industry policies such as centralized procurement, leading to a decrease in domestic prices and demand, along with adjustments in tax policies affecting gross margin [4] - The company increased its investment in the joint venture ShunJing Pharmaceutical, which became a subsidiary, resulting in significant R&D expenses that negatively impacted net profit [4] - Increased R&D investments by joint ventures like YaoJing Gene and ZhiYuan Bio in innovative drug fields have also contributed to expanded investment losses, adversely affecting the company's net profit [4]